Jacob Sheskin
Introduction '''Jacob Sheskin''', sometimes written as '''Sheskin Jacob''' (; 1914 – April 17, 1999) was a Russian-born Israeli physician best known for his 1964 serendipitous discovery that thalidomide can be used as a treatment for leprosy at Hadassah University in Jerusalem.
Awards * In 1975, the World Academy of Art and Science gave Sheskin a gold medal for his work. * in 1997, he was named Yakir Yerushalayim (), or "Worthy Citizen of Jerusalem".
Bibliography *Sheskin, J. (1975). Thalidomide in lepra reaction. ''International Journal of Dermatology, 14(8),'' 575-576. *Sheskin, J. (1975). The case for invisible leprosy. ''International Journal of Dermatology, 14(5),'' 345-346. *Sheskin, J., Sabatto, S., Yosipovitz, Z., & Ilukevich, A. (1983). Lack of wrinkle formation in the fingertips of patients with Hansen's disease. Confirmation of previous observations. Hansenologia Internationalis, 8(1),'' 54-60. *Sheskin, J. (1980). The treatment of lepra reaction in lepromatous leprosy. ''International Journal of Dermatology, 19(6),'' 318-322. *Gorodetsky, R., Sheskin, J., & Weinreb, A. (1986). Iron, copper, and zinc concentrations in normal skin and in various nonmalignant and malignant lesions. ''International Journal of Dermatology, 25(7),'' 440-445. *Wahba, A., Dorfman, M., & Sheskin, J. (1980). Psoriasis and other common dermatoses in leprosy. ''International Journal of Dermatology, 19(2),'' 93-95. *Sheskin, J. (1978). Study with nine thalidomide derivatives in the lepra reaction. ''International Journal of Dermatology, 17(1),'' 82-84. *Sheskin, J., & Zeimer, R. (1977). In vivo study of trace elements in leprous skin. ''International Journal of Dermatology, 16(9),'' 745-747.
Footnotes
References * Stevens, T., & Brynner, R. (2001), '' Dark remedy: The impact of thalidomide and its revival as a vital medicine''. Cambridge, MA: Perseus. * Joumel, L. (September–October, 2006). Four awards, one passion: Chemistry. ''CHEMISTRY International,'' 19-20. * The New England Journal of Medicine (2001). Book Reviews. ''The New England Journal of Medicine, 345(3),'' 227. * Brynner, R. (April 03, 2006). Thalidomide and Cancer. ''3 Quarks Daily. ''* Raza, A. (February, 2002). The third coming: Thalidomide and a final goodbye. ''The Biochemist''. 21-23. * BBC (January 31, 2005). The return of thalidomide ''BBC Inside Out''. * Barer, S. (2007). Celgene: The pharmaceutical phoenix. ''Chemical Heritage Magazine'', 24(4). * Lutz, K. E., (unpublished manuscript). '' From tragedy to triumph: The approval of thalidomide''. * Penna, G. O., Martelli, C. M. T., Stefani, M. M. A., Macedo, V. O., Maroja, M. d. F., & Chaul, A. (2005). Thalidomide in the treatment of erythema nodosum leprosum (ENL): Systematic review of clinical trials and prospects of new investigations. ''Anais Brasileiros de Dermatologia, 80(5),'' 511-522. * Argaw, A. T., (2004). '' A study of the anti-inflammatory, anti-microbial and immunomodulatory properties of thalidomide in leprosy''. Unpublished dissertation, Louisiana State University. * European Symposium Myeloma, Waldenstrom (2008) '' Final Report'', Annex 2, p. 19.